Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS/AZ's Forxiga joins rivals on German diabetes scrap heap

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb and AstraZeneca are the latest to join the growing club of companies withdrawing their drugs in Germany due to pricing and reimbursement difficulties. The two pharma majors have removed their diabetes drug Forxiga (dapagliflozin) from the German market pending the outcome of an arbitration procedure which is likely to grant the product a price in line with cheap sulfonylureas. Forxiga is just the latest diabetes casualty, following in the wake of Boehringer Ingelheim/ Lilly’s Tradjenta (linagliptin) and Novo Nordisk’s Tresiba (insulin degludec).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts